FibroBiologics (NASDAQ:FBLG) CFO Buys $28,700.00 in Stock

FibroBiologics Inc. (NASDAQ:FBLG) CFO Jason Davis bought 70,000 shares of FibroBiologics stock in a transaction dated Monday, March 2nd. The shares were acquired at an average price of $0.41 per share, with a total value of $28,700.00. Following the completion of the purchase, the chief financial officer directly owned 70,000 shares in the company, valued at $28,700. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

FibroBiologics Trading Up 11.6%

FBLG stock opened at $0.42 on Friday. FibroBiologics Inc. has a 1-year low of $0.22 and a 1-year high of $1.53. The business’s 50 day simple moving average is $0.30 and its 200 day simple moving average is $0.38. The firm has a market capitalization of $28.34 million, a PE ratio of -1.00 and a beta of -0.69.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.06. As a group, sell-side analysts predict that FibroBiologics Inc. will post -0.53 EPS for the current fiscal year.

Hedge Funds Weigh In On FibroBiologics

A number of hedge funds have recently bought and sold shares of the business. Yorkville Advisors Global LP bought a new position in FibroBiologics in the third quarter valued at approximately $278,000. Landscape Capital Management L.L.C. acquired a new stake in shares of FibroBiologics in the 3rd quarter valued at $191,000. Renaissance Technologies LLC boosted its holdings in shares of FibroBiologics by 287.3% in the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after purchasing an additional 171,800 shares in the last quarter. Jane Street Group LLC bought a new position in shares of FibroBiologics in the 4th quarter valued at $34,000. Finally, AMG National Trust Bank bought a new position in shares of FibroBiologics in the 4th quarter valued at $31,000.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on FBLG shares. HC Wainwright decreased their price target on shares of FibroBiologics to $4.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. D. Boral Capital reduced their price objective on FibroBiologics from $15.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, FibroBiologics has a consensus rating of “Hold” and an average target price of $5.50.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.